Announcing the new and improved Guardian Connect CGM system!

The Guardian^TM Connect system is a continuous glucose monitor (CGM), for people on multiple daily injections, that tracks glucose levels day and night and alerts of highs or lows before they happen. We’re excited to announce FDA approval for a new version of the Guardian^TM Connect system! Available summer 2020, this new version includes adjustable alert volumes, day and nighttime personalized alerts, as well as expanded access to Android™ mobile device users.   

What’s new with the Guardian^TM Connect system?  
 

Max Volume at Night 
 

We understand the importance of knowing before sugars go low or high, particularly at night. But we also understand the desire to personalize if and how you are woken up at night. 

The Guardian^TM Connect system now has a “Max Volume at Night” feature, which allows for even more alert personalization.  Now you can choose how loud your alerts are. Nighttime low and high glucose alerts will only sound as loud as you tell them to.

Adjustable Volume and Mute Alerts 
 

The Guardian^TM Connect system already has predictive alerts that can be customized to alert you 10–60 minutes in advance of a high or low. 

The new version — expected summer 2020 — will allow you to have even more control over when and how you receive these alerts. Customers using the Guardian^TM Connect CGM will have the ability to adjust their alert volumes as needed or mute audible alerts all together when it’s just not the right time for a loud alarm. (Don’t worry. If your sugar level drops to 55 mg/dL, your system will alert you of an “urgent low sensor glucose alert” with sound or vibration.)

Android Compatibility 
 

We’re also excited to announce the approval of the Guardian^TM Connect system for Android! Expanding access to Android mobile device users has been one of our top priorities. The Guardian^TM Connect CGM will be available on Samsung, LG, and Google smartphones this summer as well. 

If you use an Android smartphone and are interested in learning more, you can now opt in here.     

iOS Customers 
 

Our goal is to ensure you have a seamless transition. If you’re on an iOS device and already using Guardian^TM Connect, you should receive an email from us before the new app is released with more information about all the new features and what to expect from the update. Please be sure to update your contact information and communication preferences by visiting www.Diabetes.shop. 

Customers already on a Guardian^TM Connect system will not need to purchase a new transmitter or sensors with this new release. Visit Diabetes.shop to check your warranty. If you have any other questions call us at 888-882-8602 M–F 9AM–6PM CST. 

New customers on Android devices interested in learning more can begin to opt in here. 

Please note: only iOS customers will be able to access the Sugar.IQ app as this app is only available on iOS devices.

Collaborate with your healthcare provider & loved ones — remotely 
 

Sharing diabetes data with your healthcare provider just got even easier with the updated Assessment and Progress Report. In this new report, you can easily view your Time in Range, Guardian^TM Connect App settings, and key metrics about your stats for more informed discussions with your healthcare team. The Guardian^TM Connect system automatically uploads your data to the CareLink^TM personal software hands free — no wires required. 

You can also share your glucose alerts with loved ones with the Care Partner feature in the Guardian^TM Connect app. We first launched the Guardian Connect system in the US for iOS devices in 2018.  We’re excited to bring you an even smarter CGM and can’t wait to hear what you think!

Important Safety Information 

The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and http://www.medtronicdiabetes.com/importantsafetyinformation.   

The Sugar.IQ™ app (MMT-8100) helps manage diabetes by facilitating the logging and display of meal entries and sensor glucose (SG) data, tracking meal log entries, reporting insights of how meals affect glucose levels, and supporting good choices and trends with motivational messages. The app serves as an additional display for real-time CGM data from the Guardian™ Connect system through the CareLink™ Personal software. It is not intended to provide medical advice and should not be relied upon for such purpose. The app is not intended to replace the real-time display of the CGM data on the Guardian™ Connect app, control any functions of the connecting device, calculate insulin or other drug doses, or modify date or control functions of the Guardian™ Connect system. All therapy decisions should be made by the app user based on blood glucose (BG) measurements obtained from a BG meter. Changes to treatment should only be made in consultation with a healthcare professional (HCP). For complete details, consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides.&…;

The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices and not on values provided by the system.   

The CareLink™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink™ reports. The reports provide information that can be used to identify trends and track daily activities—such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: CareLink™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment. For more details, please consult http://www.medtronicdiabetes.com/ImportantSafetyInformation  and the appropriate CareLink™ User Guide at http://www.medtronicdiabetes.com/support/download-library/user-guides.   

Android is a trademark of Google LLC. 

© 2024 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. All other brands are trademarks of a Medtronic company.